August 22, 2025

Supplementary Figure S1 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Phase 1b/2 study demonstrates treatment approach for acute myeloid leukemia in patients age 60+, suggesting potential benefits.

Treatment improved outcomes in patients with acute myeloid leukemia aged 60 and older, indicating promise for targeted therapies.
Key evidence showed promising response rates with tp-0903 and decitabine in treating mutant tp53 and complex karyotype cases.
Phase 1b/2 study assessed the efficacy of a combined treatment approach using tp-0903 and decitabine in older patients with untreated conditions.
Findings support the need for targeted strategies in managing acute myeloid leukemia, particularly for complex genetic profiles.

Eisenmann et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark